pharmaphorum

MARCH 13, 2024

Basecamp Research launches BaseFold, a deep learning model that it says surpasses benchmark tool AlphaFold2 and should accelerate AI-based drug discovery.

Protein 89

Protein Research Drugs 89

Pharmaceutical Technology

JUNE 15, 2023

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. This method can target enzymes, transcription factors, scaffold proteins and more.

Protein 130

Protein Development Licensing Licensing 130

Pharma Times

APRIL 29, 2024

The new process makes generating active pharmaceutical ingredients quicker and easier

Protein 137

Protein Development Research Drugs 137

Pharma Times

DECEMBER 20, 2023

Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. However, its relation to dopaminergic neuron death is unclear.

Protein 96

Protein Medicine Engineer Genetics 96

XTalks

MARCH 31, 2023

BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.

Protein 97

Protein Research Development Manufacturing 97

pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins. These regions are critical for optimal interactions between proteins.

Protein 125

Protein Gene Bioassay DNA 125

Bio Pharma Dive

JULY 26, 2022

Known as tofersen, the drug failed in the main study being used to support its approval. But an apparent effect on a protein of interest in ALS research has Biogen convinced the treatment will pass muster with regulators.

Drugs 321

Drugs Protein Regulation Research 321

BioPharma Reporter

AUGUST 10, 2023

Evox Therapeutics, an exosome therapeutics company, has announced the publication of its research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes.

Protein 52

Protein Research Drugs Development 52

Pharmaceutical Technology

FEBRUARY 16, 2023

Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors.

Protein 147

Protein Development Sales Business Development 147

Bio Pharma Dive

JUNE 16, 2023

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.

FDA Approval 177

FDA Approval Drugs Protein Antibody 177

Bio Pharma Dive

MARCH 30, 2021

Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis.

Life Science 306

Life Science Drugs Trials Protein 306

Pharmaceutical Technology

MARCH 17, 2023

The Lung Cancer Research Foundation (LCRF) has announced a new research partnership with Daiichi Sankyo and AstraZeneca. This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients.

Research 246

Research Antibody Protein Trials 246

pharmaphorum

MARCH 13, 2024

Basecamp Research launches BaseFold, a deep learning model that it says surpasses benchmark tool AlphaFold2 and should accelerate AI-based drug discovery

Protein 113

Protein Drugs Research 113

Drug Discovery World

NOVEMBER 14, 2022

New research about how cancer-related proteins bind copper ions opens up potential new drug targets to treat cancer. . Higher levels of copper also mean more active copper-binding proteins. . Higher levels of copper also mean more active copper-binding proteins. . Protecting cancer cells. Image caption: ?The

Protein 52

Protein Drugs Research Gene 52

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Discover the top API protein and peptide companies in contract marketing. Technologies in the delivery of peptides and proteins. They are promising therapeutics for the treatment of a variety of metabolic and oncological disorders.

Protein 130

Protein Marketing Manufacturing Reagent 130

Medical Xpress

NOVEMBER 8, 2022

Researchers at the University of Maryland School of Medicine's (UMSOM) Center for Precision Disease Modeling identified how a specific protein in SARS-CoV-2, the virus responsible for COVID-19, damages heart tissue. They then used a drug to reverse the toxic effects of that protein on the heart.

Protein 98

Protein Medicine Drugs Research 98

Scienmag

JUNE 2, 2022

Mechanisms associated with a particular diabetes drug can also help to protect against Alzheimer’s disease, a study by researchers at Karolinska Institutet in Sweden and published in Neurology reports. The results indicate that the drug’s target protein can be an interesting candidate for the treatment of Alzheimer’s disease.

Protein 76

Protein Drugs Research 76

Drug Discovery World

APRIL 17, 2024

Arvinas’ AR-V7-targeting PROTAC protein degrader is designed to target both AR-V7 and full-length AR. This strategic transaction also further validates our innovative PROTAC protein degrader platform and its potential to deliver new treatments.”

Protein 52

Protein Licensing Licensing Sales 52

Drug Discovery World

MARCH 5, 2024

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head.

Antibody 59

Antibody Protein Vaccination Vaccine 59

Pharma Mirror

OCTOBER 16, 2023

by Carrie Taylor, Director of Research & Development of BOCSCI. The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021.

Immune Response 130

Immune Response Drugs Protein Vaccination 130

Bio Pharma Dive

DECEMBER 1, 2022

Detailed clinical trial data for Roche's gantenerumab showed treatment cleared far less toxic protein from patients' brains than expected, potentially explaining its divergent result from Eisai’s lecanemab.

Clinical Trials 161

Clinical Trials Clinical Trials Protein Research 161

Drug Discovery World

APRIL 3, 2024

In the last few years, immunotherapies like immune checkpoint inhibitors, vaccines and cell and gene therapies have revolutionised the treatment of cancer, and targeted drugs like monoclonal antibodies (mAbs), poly-ADP ribose polymerase (PARP) inhibitors and targeted protein degraders are also playing an important role.

Research 52

Research Drugs Gene Therapy Genetics 52

BioTech 365

JULY 20, 2021

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs In Development, 2021 Research Report – ResearchAndMarkets.com Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs In Development, 2021 Research Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Bromodomain Containing Protein 4 (Protein (..)

Protein 40

Protein Containment Development Research 40

Drug Discovery World

FEBRUARY 13, 2024

It goes on to show that NX-2127, a potent targeted protein degrader with differentiated activity against BTK and IKZF1/3, can overcome this resistance across a broad range of acquired mutations. The post Protein degrader overcomes resistance in B-cell malignancies appeared first on Drug Discovery World (DDW).

Protein 52

Protein Medicine Scientist Research 52

pharmaphorum

SEPTEMBER 2, 2020

With protein misfolding and aggregation prevalent in neurodegeneration, cancer, metabolic and ophthalmic diseases, the unmet clinical need presents huge opportunity to accelerate the discovery and translation of novel therapeutics to transform patient outcomes. Optimize drug pharmacology.

Protein 52

Protein Drugs Research Development 52

Drug Discovery World

NOVEMBER 25, 2022

Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs. . Better, less toxic drugs. The post Bowel cancer protein study could lead to less toxic cancer drugs appeared first on Drug Discovery World (DDW).

Protein 52

Protein Drugs Scientist Research 52

Drug Discovery World

MAY 4, 2023

Adaptyv Bio, a Swiss/US technology company that develops infrastructure and tools for protein designers to engineer better proteins, has built a protein engineering foundry that it says will “pave the way” for protein designers to develop new medicines, novel enzymes and sustainable materials.

Engineer 52

Engineer Protein Life Science Medicine 52

Medical Xpress

APRIL 26, 2023

Researchers at Nagoya University in Japan have discovered a receptor, sigma-1 receptor, and a protein, ATAD3A, that are associated with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. Since there are drugs that specifically target the receptor, their findings suggest a new therapeutic strategy.

Protein 91

Protein Drugs Research 91

Medical Xpress

APRIL 13, 2023

CU Boulder researchers have discovered a protein's crucial role in helping breast and ovarian tumors survive and thrive and have found that suppressing that protein kills cancer cells without harming healthy ones.

Research 98

Research Protein Drugs 98

The Pharma Data

APRIL 26, 2022

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, according to a new study by researchers at the Indian Institute of Science (IISc). Targeting Nsp1 could therefore reduce the damage inflicted by the virus.

Protein 52

Protein Drugs Allergies FDA Approval 52

Roots Analysis

MARCH 2, 2022

Orally administrable protein / peptide-based therapeutics offer several advantages including, effective treatment of numerous clinical conditions and degenerative disorders. Over 40 oral drug delivery technologies have been designed so far. Pipeline Overview of Oral Peptide and Protein-based Therapeutics.

Protein 52

Protein Drug Delivery Drugs Drug Delivery Systems 52

Bio Pharma Dive

SEPTEMBER 7, 2023

The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close.

Protein 177

Protein Antibody Drugs Research 177

Drug Discovery World

FEBRUARY 14, 2024

The researchers suggested that if this tool had been deployed at the start of the pandemic, it would have accurately identified which variants of SARS-CoV-2 had the highest escape potential. However, such achievements can only be achieved by leveraging research strengths, regulatory capabilities and technical platforms.

Protein 59

Protein Vaccination Vaccine Manufacturing 59

Drug Discovery World

JANUARY 26, 2023

This is the latest episode of the free narrated DDW podcast, “CRO’s and targeted protein degradation offer an exciting future”. They are called “ CROs: Drug discovery expertise on hand ” and “ Why the emergence of targeted protein degradation is so exciting ”.

Protein 52

Protein Drugs Research Marketing 52

Drug Discovery World

NOVEMBER 7, 2023

As more and more R&D pipelines include PROTAC candidates — the race to bring successful and efficient protein degraders to the clinic is on. These targets present challenges in the biophysical characterisation of binary and ternary complexes, making developing effective degraders complicated.

Protein 52

Protein Development Drugs Research 52

Drug Discovery World

JULY 24, 2023

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Protein 52

Protein Manufacturing Gene Sequencing Production 52

Drug Discovery World

JANUARY 26, 2024

Researchers from Tokyo University of Science (TUS) have found a simple, low-cost way to optimise the production of monoclonal antibodies (mAbs) and reduce manufacturing costs. During ER stress response, protein folding ceases, resulting in the arrest of the normal function of cells.

Antibody 102

Antibody Research Protein Production 102